Patents by Inventor George Kuo
George Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7790366Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: GrantFiled: May 15, 1995Date of Patent: September 7, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Publication number: 20080318275Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: ApplicationFiled: March 17, 2008Publication date: December 25, 2008Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Publication number: 20080191854Abstract: A method for actuating a controlled device in response to a pre-crash condition of a vehicle, wherein the vehicle includes at least two sensors each of which is capable of generating a signal, wherein the method includes the steps of monitoring the signals, determining a panic index based upon the signals and, when the determined panic index exceeds a predetermined threshold value, actuating the controlled device.Type: ApplicationFiled: February 14, 2007Publication date: August 14, 2008Inventors: Deron C. LittleJohn, Ching C. (George) Kuo, Sanket S. Amberkar
-
Publication number: 20060292556Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: ApplicationFiled: November 9, 2005Publication date: December 28, 2006Applicant: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 7138505Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage ?FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.Type: GrantFiled: August 13, 1990Date of Patent: November 21, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: George Kuo, Frank Masiarz, Martha Truett, Pablo Valenzuela, Mirella Ezban Rasmussen, Daniel Caput, Rae Lyn Burke, Carol Pachl
-
Patent number: 7105303Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: GrantFiled: August 13, 2001Date of Patent: September 12, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Publication number: 20050202418Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: ApplicationFiled: December 28, 2004Publication date: September 15, 2005Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Publication number: 20050089843Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: ApplicationFiled: October 12, 2004Publication date: April 28, 2005Inventors: Robert Ralston, Frank Marcus, Kent Thudium, Barbara Gervase, John Hall, Kim Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Patent number: 6861212Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: GrantFiled: May 15, 1995Date of Patent: March 1, 2005Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Publication number: 20040091851Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.Type: ApplicationFiled: November 12, 2002Publication date: May 13, 2004Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Publication number: 20030232328Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.Type: ApplicationFiled: March 14, 2003Publication date: December 18, 2003Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Publication number: 20030162167Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.Type: ApplicationFiled: July 25, 1996Publication date: August 28, 2003Inventors: MICHAEL HOUGHTON, QUI-LIM CHOO, GEORGE KUO
-
Publication number: 20030064499Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.Type: ApplicationFiled: June 18, 2001Publication date: April 3, 2003Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Publication number: 20030027317Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteaces are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.Type: ApplicationFiled: June 18, 2001Publication date: February 6, 2003Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Patent number: 6485113Abstract: A haptic braking method and system is disclosed. A controller operates a pump to apply brake fluid to a brake when it is necessary to decelerate a wheel during an active cruise control mode of a vehicle. The controller further operates one or more valves to cyclically vary a pressure level of the brake fluid to cause one or more haptic movements of the brake.Type: GrantFiled: March 8, 2001Date of Patent: November 26, 2002Assignee: Delphi Technologies, Inc.Inventors: Hubert B. Riley, George Kuo
-
Publication number: 20020125769Abstract: A haptic braking method and system is disclosed. A controller operates a pump to apply brake fluid to a brake when it is necessary to decelerate a wheel during an active cruise control mode of a vehicle. The controller further operates one or more valves to cyclically vary a pressure level of the brake fluid to cause one or more haptic movements of the brake.Type: ApplicationFiled: March 8, 2001Publication date: September 12, 2002Applicant: DELPHI TECHNOLOGIES INC.Inventors: Hubert B. Riley, George Kuo
-
Patent number: 6416946Abstract: The present invention provides methods and compositions for use therein for typing hepatitis C viruses.Type: GrantFiled: November 9, 1999Date of Patent: July 9, 2002Assignee: Chiron CorporationInventors: David Y. Chien, George Kuo
-
Patent number: 6416944Abstract: The claimed invention provides methods of detecting and typing HCV using nucleic acid molecules encoding type specific and type-cluster specific epitopes. The nucleic acid molecules flanking regions encoding type specific or type cluster specific epitopes are useful in priming the polymerase chain reaction to determine the genotype an HCV isolate.Type: GrantFiled: May 11, 1995Date of Patent: July 9, 2002Assignee: Chiron CorporationInventors: David Y. Chien, George Kuo
-
Publication number: 20020004048Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: ApplicationFiled: August 13, 2001Publication date: January 10, 2002Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Patent number: 6312889Abstract: Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.Type: GrantFiled: May 12, 1995Date of Patent: November 6, 2001Assignee: Chiron CorporationInventors: Michael Houghton, Qui-Lim Choo, George Kuo